Posted by Michael Wonder on 31 Aug 2023
InflaRx’s marketing authorisation application for vilobelimab for treatment of critically ill COVID-19 patients under review by European Medicines Agency
30 August 2023 - Regulatory submission based on pivotal data from PANAMO Phase III trial.
InflaRx announced today that the Company has submitted a marketing authorisation application for the treatment of adult patients with SARS-CoV-2 induced septic acute respiratory distress syndrome receiving invasive mechanical ventilation or extracorporeal membrane oxygenation and that the EMA has validated the application.
